Updates from Gastrointestinal ASCO 2015

Area of Science:

• Gastroenterology
• Medical Oncology
• Surgical Oncology

Background:

• Gastrointestinal (GI) malignancies represent a significant global health burden.
• Optimal treatment strategies for various GI cancers are continually evolving.
• Recent advancements presented at ASCO GI offer new insights into managing these diseases.

Purpose of the Study:

• To review key data presented at the ASCO GI meeting.
• To discuss the implications of new findings on the treatment of GI cancers.
• To highlight advancements in surgical and systemic therapies for GI malignancies.

Main Methods:

• Retrospective analysis of rectal tumor patients to assess surgical avoidance.
• Review of Phase III RAISE trial data for ramucirumab in advanced colorectal cancer.
• Examination of KEYNOTE-012 trial results for pembrolizumab in advanced gastric cancer.

Main Results:

• A retrospective study suggested that certain rectal tumor subgroups may avoid surgery without impacting survival.
• The RAISE trial demonstrated that adding ramucirumab to second-line therapy significantly improved overall survival in advanced colorectal cancer.
• The KEYNOTE-012 trial reported an objective response rate of 22.1% and 6-month progression-free survival of 24% with pembrolizumab in advanced gastric cancer.

Conclusions:

• Emerging data suggest non-operative management may be feasible for select rectal cancer patients.
• Ramucirumab shows promise as a valuable addition to second-line treatment for advanced colorectal cancer.
• Immunotherapy, specifically pembrolizumab, demonstrates notable efficacy in advanced gastric cancer, warranting further investigation.